MOUNTAIN VIEW, Calif., May 17 /PRNewswire/ -- ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, announced that data from the company’s Phase 2 clinical trial of Traficet-EN(R) (CCX282-B), targeting the chemokine receptor CCR9, will be presented at the upcoming Digestive Disease Week (DDW) meeting in Washington D.C. being held May 19-23, 2007.
Positive data demonstrating the safety and clinical benefits of once daily oral administration of Traficet-EN among Crohn’s disease patients will be detailed in the following two sessions at the Washington Convention Center during DDW.
1. Tuesday, May 22, 2007 at 3:25 p.m. Room 103 Top-line results from the Phase 2 trial will be highlighted as part of the “Best of UEGW” session sponsored by the American Gastroenterological Association (AGA). 2. Wednesday, May 23, 2007 at 4:45 p.m. Room 207 Detailed results from ChemoCentryx’s Phase 2 randomized clinical trial will be provided in an oral presentation (#1031) titled “CCX282-B, an orally active inhibitor of chemokine receptor CCR9, shows anti-inflammatory and clinical activity in the treatment of Crohn’s Disease” by Satish Keshav, M.D., Ph.D., Gastroenterologist at the John Radcliffe Hospital, Oxford during the “Advances in Crohn’s Disease” session.
Traficet-EN, a small molecule, orally-available drug, is intended to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the activity of the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn’s disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in Crohn’s disease. ChemoCentryx has completed four Phase I trials and one four-week Phase 2 trial of Traficet-EN demonstrating that the product candidate is well-tolerated and appropriate for once- or twice-daily oral dosing. Currently, Traficet-EN is being tested in the PROTECT-1 trial, a multi-national study in patients with moderate-to-severe Crohn’s disease.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a complex network of chemokine molecules, or ligands, and receptors that regulates inflammation. Based on their proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx’s lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn’s disease. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.
Any statements in this press release about ChemoCentryx’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward- looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the timing, success and cost of preclinical research and clinical studies, (ii) the timing, acceptability and review periods for regulatory filings, (iii) the availability of corporate partners, (iv) uncertainties relating to patent protection and intellectual property rights of third parties, (v) the impact of competitive products and technological changes, (vi) the availability of capital and the cost of capital, (vii) other vagaries in the biotechnology industry and (viii) other risks. ChemoCentryx undertakes no obligation to update or revise any forward- looking statements.
ChemoCentryx, Inc.
CONTACT: Susan M. Kanaya, Senior Vice President, Finance and ChiefFinancial Officer, or Markus J. Cappel, Ph.D., Chief Business Officer, bothof ChemoCentryx, +1-650-210-2900, or investor@chemocentryx.com; or media,Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662,both of BCC Partners
Web site: http://www.chemocentryx.com//
